Interim safety results from TRUST, a global open-label study of erlotinib in patients with advanced non-small-cell lung cancer (NSCLC)

被引：3

作者：

Ardizzoni, Andrea

Razis, Evangelia

Lichinitser, Mikhail

Yilmaz, Ugur

Grigorescu, Alexandru C.

Morero, Jose Luis

Skrickova, Jana

Cervantes, Guadalupe

Gottfried, Maya

Van Meerbeeck, Jan

机构：

[1] Univ Parma, Parma, Italy

[2] Hygeia Hosp, Athens, Greece

[3] NN Blochin Russian Oncol Res Ctr, Moscow, Russia

[4] Dokuz Eylu Univ, Med Fac, Izmir, Turkey

[5] Bucharest Oncol Inst, Bucharest, Romania

[6] Hosp Maria Ferrer, Buenos Aires, DF, Argentina

[7] Univ Hosp Brno, Brno, Czech Republic

[8] ISSSTE, Hosp Noviembre Ctr Medico, Mexico City, DF, Mexico

[9] Meir Sapir Med Ctr, Kefar Sava, Israel

[10] Univ Hosp, Ghent, Belgium

来源：

关键词：

D O I：

10.1097/01.JTO.0000283158.26734.bc

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：S342 / S342

页数：1